Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-30
2005-08-30
Li, Q. Janice (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S093210, C424S450000, C435S320100
Reexamination Certificate
active
06936594
ABSTRACT:
By introducing hepatocyte growth factor (HGF) gene and/or vascular endothelial growth factor (VEGF) gene into the subarachnoid space in humans, cerebrovascular disorders such as cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral bleeding, moyamoya disease, cerebrovascular dementia, and Alzheimer's dementia can be effectively treated or prevented.
REFERENCES:
patent: 4686085 (1987-08-01), Osterholm
patent: 5652225 (1997-07-01), Isner
patent: 6121246 (2000-09-01), Isner
patent: 6199554 (2001-03-01), Mann et al.
patent: 6248722 (2001-06-01), Morishita et al.
patent: 0 847 757 (1998-06-01), None
patent: 7-41429 (1995-02-01), None
patent: 8-231416 (1996-09-01), None
patent: 11-246434 (1999-09-01), None
patent: 95/07709 (1995-03-01), None
patent: WO 96/26742 (1996-09-01), None
patent: WO 9707824 (1997-03-01), None
patent: WO 97/14307 (1997-04-01), None
patent: 97/14307 (1997-04-01), None
patent: WO 97/30155 (1997-08-01), None
patent: WO 99/21590 (1999-05-01), None
patent: WO 99/36103 (1999-07-01), None
Yonemitsu et al, Gene Ther 1997;4:631-8.
Wang et al, Biochem Biophy Comm 1998;244:449-54.
Rosengart et al, Circulation 1999;100:468-74.
Furlan et al, Hum Gene Ther 1998;9:2605-17.
Ghodsi et al, Hum Gene Ther 1998;9:2331-40.
de Lecinana et.al.; Cerebral ischemia: from animal studies to clinical practice. Should the methods be reviewed?, 2001, Cerebrovasc Dis 11: 20-30.
Orkin et.al.; Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995: 1-37.
Verma et.al.; gene therapy- promises, problems and prospects, 1997, Nature, vol. 389: 239-242.
Rozenberg et.al.; Alternative gene delivery, 2001,S.T.P. Pharma Sciences 11: 21-30.
Nishikawa et.al.; Nonviral Vectors in the New Millennium: Delivery Barriers in Gene Transfer, 2001, Human Gene Therapy 12: 861-870.
Balicki et.al.; Reviews in Molecular Medicine, 2002, Medicine 81: 69-86.
Castro et.al.; Gene therapy for Parkinson's disease: recent achievements and remaining challenges, 2001, History and Histopathology 16: 1225-1238.
Chinese Office Action for Chinese Patent Application No. 00802004.3 dated Feb. 4, 2004.
John Laterra, et al., “Scatter Factor/Hepatocyte Growth factor Gene Transfer Enhances Glioma Growth and Angiogenesis In Vivo”, Laboratory Investigation, vol. 76, No. 4, pp. 565-577, 1997 and PubMed Abstract.
International Search Report.
Adventure in Gene Theray: “MEDGENE” as the First Academic Genetic Bioventure, BIOJAPAN 2000 Symposium Proceedings, pp. 183-193 (Presented on Sep. 27, 2000).
International Search Report Dec. 2000.
Adventure in Gene Theray: “MEDGENE” as the First Academic Genetic Bioventure, BIOJAPAN 2000 Symposium Proceedings, pp. 183-193 (Presented on Sep. 27, 2000).
Taiwanese Office Action, Feb. 3, 2005.
Papavassiliou E., et al., “Vascular endothelial growth factor (vascular permeability factor) expression in injured rat brain.” J Neurosci Res., Aug. 15, 1997, vol. 49(4) pp. 451-460.
Issa R., et al., “Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke.” Lab Invest. Apr., 1999, vol. 79(4), pp. 417-425.
Morishita Ryuichi
Ogihara Toshio
Anges Mg, Inc.
Li Q. Janice
Morishita Ryuichi
LandOfFree
Gene therapy for cerebrovascular disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene therapy for cerebrovascular disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy for cerebrovascular disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477367